文献速递间质性肺疾病

Efzofitimod对比安慰剂治疗肺结节病:EFZO-FIT三期随机双盲试验

Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2026-10-26

EFZO-FIT多中心三期试验纳入264例需治疗的肺结节病患者,随机接受efzofitimod 3 mg/kg、5 mg/kg或安慰剂静脉输注48周并口服激素递减。主要终点第48周日均口服激素剂量变化在组间无差异,efzofitimod耐受性良好但未能减少激素用量。

要点

  • efzofitimod 3 mg/kg和5 mg/kg与安慰剂相比未显著降低第48周口服激素剂量。
  • efzofitimod耐受性良好,严重不良事件发生率与安慰剂相似。
  • 激素递减方案可使多数肺结节病患者口服激素降至较低剂量。

核心结论

  • efzofitimod耐受性良好,但与安慰剂相比未能在第48周降低口服激素剂量。
  • 激素递减结果提示许多肺结节病患者的口服激素可更积极减量。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照三期试验,在9个国家85个中心纳入18-75岁需治疗的肺结节病成人。
  • 268例随机1:1:1接受每月静脉efzofitimod 3 mg/kg、5 mg/kg或安慰剂,治疗48周,含12周口服激素递减至目标0 mg/天。
  • 264例接受至少一剂研究药物且至少一次基线后疗效评估者纳入结局和安全性分析。

主要发现

  • 第48周口服激素剂量安慰剂校正的基线变化:efzofitimod 3 mg/kg组0·02 mg/天(95%CI -1·49至1·52,p=0·98),5 mg/kg组-0·73 mg/天(95%CI -2·21至0·75,p=0·33)。
  • 严重治疗中出现不良事件发生率组间相似;安慰剂组不适更常见(5/90[6%] vs 两个efzofitimod组均为0)。
  • efzofitimod组更常见的不良事件包括头痛(5 mg/kg组17/88[19%]、3 mg/kg组11/86[13%]、安慰剂组4/90[4%])、鼻窦炎(分别为9[10%]、6[7%]、2[2%])、喘息(7[8%]、2[2%]、0)和AST升高(5[6%]、1[1%]、0)。
  • 大多数不良事件为1级或2级;2例死亡均发生在efzofitimod 3 mg/kg组(呼吸衰竭和原有腹股沟疝嵌顿),均判定与治疗无因果关系。

临床怎么用

  • efzofitimod目前证据不支持作为肺结节病的激素节省剂常规使用。
  • 肺结节病患者口服激素可按方案积极递减,但需警惕疾病恶化并允许上调剂量。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral corticosteroids are currently standard-of-care therapy for pulmonary sarcoidosis, but they are associated with substantial toxicity and reduced health-related quality of life (HRQoL). The EFZO-FIT trial aimed to assess the efficacy and safety of efzofitimod, a novel immunomodulatory fusion protein targeting the neuropilin 2 receptor, as a steroid-sparing agent in pulmonary sarcoidosis. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, adults aged 18-75 years with pulmonary sarcoidosis requiring treatment were enrolled at 85 study centres across nine countries (Brazil, France, Germany, Italy, Japan, Netherlands, Spain, UK, and USA). Participants were randomly assigned 1:1:1 using stratified block randomisation to receive monthly intravenous infusions of efzofitimod 3 mg/kg, efzofitimod 5 mg/kg, or placebo over a 48-week treatment period, including a 12-week oral corticosteroid taper targeting 0 mg per day (starting on day 15). Oral corticosteroid dose could be adjusted upwards in the event of worsening sarcoidosis. The primary endpoint was change from baseline in mean daily oral corticosteroid dose at week 48. Outcome and safety analyses were done in participants who received at least one dose of the study drug and had at least one post-baseline efficacy assessment. This study was registered with ClinicalTrials.gov (NCT05415137) and is complete. FINDINGS: Between Sept 22, 2022, and Aug 14, 2025, 331 patients were screened for inclusion. 63 were excluded and 268 participants were randomly assigned to receive placebo (n=91), efzofitimod 3 mg/kg (n=89), or efzofitimod 5 mg/kg (n=88). Four patients were excluded after random assignment (one in the placebo group and three in the efzofitimod 3 mg/kg group). 264 patients who received at least one dose of study treatment and had at least one post-baseline assessment were included in the outcome analysis and safety population (90 in the placebo group, 86 in the efzofitimod 3 mg/kg group, and 88 in the efzofitimod 5 mg/kg group). Among the 264 participants, the mean age was 53·8 years (SD 10·6); 114 (43%) of 264 patients were female and 150 (57%) were male. 168 (64%) identified as White. Mean steroid dose was 10·7 mg per day (SD 4·4) at baseline and 2·9 mg per day (4·5) at week 48. No difference was seen in the magnitude of oral corticosteroid taper between the active and placebo dose groups; the placebo-adjusted change from baseline was 0·02 mg per day in the efzofitimod 3 mg/kg group (95% CI -1·49 to 1·52, p=0·98) and -0·73 mg per day in the efzofitimod 5 mg/kg group (-2·21 to 0·75, p=0·33). The percentage of participants with serious treatment-emergent adverse events was similar between groups. Malaise was more common in the placebo group (five [6%] of 90 patients vs zero in both efzofitimod groups). TEAEs that were more common in the efzofitimod groups included headache (17 [19%] of 88 patients in the efzofitimod 5 mg/kg group, 11 [13%] of 86 patients in the efzofitimod 3 mg/kg group, and four [4%] of 90 patients in the placebo group), sinusitis (nine [10%], six [7%], and two [2%] patients, respectively), wheezing (seven [8%], two [2%], and zero patients, respectively), and aspartate aminotransferase (AST) increased (five [6%], one [1%], and zero patients, respectively). Most adverse events were grade 1 or 2. Two participants died, both in the efzofitimod 3 mg/kg group (one respiratory failure and one incarceration of a pre-existing inguinal hernia). Neither event was considered to be causally related to the treatment. INTERPRETATION: Efzofitimod was well tolerated but did not result in lower steroid doses at week 48 compared with placebo. The results from steroid tapering indicate that oral corticosteroid doses can be more aggressively reduced in many patients with pulmonary sarcoidosis. FUNDING: aTyr and Kyorin.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Culver DA, Bonella F, Gupta R, et al. Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2026. PMID: 42933455. doi:10.1016/S2213-2600(26)00283-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。